Goodwin Procter advised Deciphera Pharmaceuticals, and Davis Polk advised the joint book-running managers involved in the offering.Deciphera Pharmaceuticals Inc. announced a $135.1 million SEC-registered common stock offering….
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
